References
- Schouten HC, Qian W, Kvaloy S, et al. High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial. J Clin Oncol 2003;21:3918–3927.
- Hamlin PA, Zelenetz AD, Kewalramani T, et al. Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma. Blood 2003;102:1989–1996.
- Pedersen LM, Klausen TW, Davidsen UH, et al. Early changes in serum IL-6 and VEGF levels predict clinical outcome following first-line therapy in aggressive non-Hodgkin's lymphoma. Ann Hematol 2005;84:510–516.
- Dickinson M, Hoyt R, Roberts AW, et al. Improved survival for relapsed diffuse large B cell lymphoma is predicted by a negative pre-transplant FDG-PET scan following salvage chemotherapy. Br J Haematol 2010;150:39–45.
- Pedersen LM, Jürgensen GW, Johnsen HE. Serum levels of inflammatory cytokines at diagnosis correlate to the bcl-6 and CD10 defined germinal centre (GC) phenotype and bcl-2 expression in patients with diffuse large B-cell lymphoma. Br J Haematol 2005;128:813–819.
- Mylin AK, Rasmussen T, Johansen JS, et al. Serum YKL-40 concentrations in newly diagnosed multiple myeloma patients and YKL-40 expression in malignant plasma cells. Eur J Haematol 2006;77:416–424.
- Biggar RJ, Johansen JS, Smedby KE, et al. Serum YKL-40 and interleukin 6 levels in Hodgkin lymphoma. Clin. Cancer Res 2008; 14:6974–6978.
- He CH, Lee CG, Dela Cruz CS, et al. Chitinase 3-like 1 regulates cellular and tissue responses via IL-13 receptor α2. Cell Rep 2013;4: 830–841.
- Karin M, Greten FR. NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 2005;5:749–759.
- Dave S. Gene expression profiling and outcome prediction in non-Hodgkin lymphoma. Biol Blood Marrow Transplant 2006; 12(Suppl. 1):50–52.